[go: up one dir, main page]

PE20091882A1 - Encapsulacion de agentes biologicamente activos - Google Patents

Encapsulacion de agentes biologicamente activos

Info

Publication number
PE20091882A1
PE20091882A1 PE2009000606A PE2009000606A PE20091882A1 PE 20091882 A1 PE20091882 A1 PE 20091882A1 PE 2009000606 A PE2009000606 A PE 2009000606A PE 2009000606 A PE2009000606 A PE 2009000606A PE 20091882 A1 PE20091882 A1 PE 20091882A1
Authority
PE
Peru
Prior art keywords
biologically active
aqueous
encapsulation
particles
add
Prior art date
Application number
PE2009000606A
Other languages
English (en)
Inventor
Mehmet Fidanboylu
Irene Papanicolaou
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40944671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091882(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20091882A1 publication Critical patent/PE20091882A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

SE REFIERE A UN PROCESO PARA PRODUCIR UN VEHICULO EN FORMA DE PARTICULAS COMO MICROESFERAS QUE COMPRENDE: A) DISOLVER POLIBUTILCIANOACRILATO (PBCA) EN UN DISOLVENTE ORGANICO PARA FORMAR UNA SOLUCION POLIMERICA Y ADICIONAR UN AGENTE FORMADOR DE GEL TAL COMO AGAROSA; B) ANADIR UNA SOLUCION ACUOSA QUE CONTIENE UN AGENTE BIOLOGICAMENTE ACTIVO TAL COMO UN PEPTIDO, PROTEINA, ANTICUERPO, ENTRE OTROS, A LA SOLUCION POLIMERICA PARA FORMAR UNA EMULSION PRIMARIA DE GOTAS DE FASE ACUOSA EN UNA FASE ORGANICA CONTINUA; C) MEZCLAR LA EMULSION PRIMARIA CON UN MEDIO ACUOSO PARA FORMAR UNA EMULSION SECUNDARIA; Y D) PERMITIR QUE LA FASE ORGANICA SE EVAPORE Y OBTENER VEHICULOS EN FORMA DE PARTICULAS QUE COMPRENDEN UNA LUZ HUECA QUE CONTIENE EL AGENTE BIOLOGICAMENTE ACTIVO EN UNA FASE ACUOSA
PE2009000606A 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos PE20091882A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
PE20091882A1 true PE20091882A1 (es) 2009-12-24

Family

ID=40944671

Family Applications (4)

Application Number Title Priority Date Filing Date
PE2009000609A PE20091965A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000607A PE20091829A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000608A PE20091964A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000606A PE20091882A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PE2009000609A PE20091965A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000607A PE20091829A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000608A PE20091964A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos

Country Status (11)

Country Link
US (1) US20110064821A1 (es)
EP (2) EP2271323A2 (es)
JP (1) JP2011522792A (es)
KR (3) KR20110010760A (es)
AR (4) AR072668A1 (es)
CA (1) CA2721241A1 (es)
CL (4) CL2009001081A1 (es)
PE (4) PE20091965A1 (es)
TW (4) TW201012490A (es)
UY (4) UY31810A (es)
WO (1) WO2009135853A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064819A1 (en) * 2008-05-06 2011-03-17 Andrew Beaton Encapsulation of biologically active agents
WO2013021353A1 (en) 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
WO2015181346A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
US20170189345A1 (en) * 2014-05-30 2017-07-06 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
US20150359804A1 (en) * 2014-06-12 2015-12-17 Orbis Biosciences, Inc. Extended-release drug delivery compositions
EP3160449B1 (en) 2014-06-24 2023-12-13 The Trustees of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
WO2019090030A1 (en) * 2017-11-03 2019-05-09 Prudhomme Robert K Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
WO2020018890A1 (en) 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US20220031630A1 (en) * 2018-09-13 2022-02-03 The Brigham And Women's Hospital, Inc. Nanoparticle formulations and methods of their use
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833666A (en) 1986-12-24 1989-05-23 U.S. Philips Corporation Disc-record player suitable for scanning disc of different types
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
AU3462193A (en) * 1993-02-15 1994-08-29 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
EP0717617B1 (de) * 1993-09-09 2000-10-25 Schering Aktiengesellschaft Wirkstoffe und gas enthaltende mikropartikel
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
CA2452382A1 (en) * 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
CA2531238C (en) 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
JP2008513363A (ja) 2004-09-14 2008-05-01 ナノデル テクノロジーズ ゲーエムベーハー ナノ粒子を含む送達媒体
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8227576B2 (en) 2006-03-30 2012-07-24 Glaxo Group Limited Antibodies against amyloid-β peptide
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
NZ580530A (en) 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery

Also Published As

Publication number Publication date
TW201012488A (en) 2010-04-01
KR20110015604A (ko) 2011-02-16
AR071634A1 (es) 2010-06-30
UY31807A (es) 2009-12-14
UY31810A (es) 2009-12-14
WO2009135853A3 (en) 2011-05-12
CL2009001080A1 (es) 2010-09-24
CL2009001081A1 (es) 2010-09-24
AR072668A1 (es) 2010-09-15
KR20110010760A (ko) 2011-02-07
PE20091964A1 (es) 2010-01-09
TW201006495A (en) 2010-02-16
TW201012489A (en) 2010-04-01
UY31808A (es) 2009-12-14
PE20091965A1 (es) 2010-01-09
AR072359A1 (es) 2010-08-25
WO2009135853A2 (en) 2009-11-12
CL2009001077A1 (es) 2010-09-24
EP2441447A1 (en) 2012-04-18
TW201012490A (en) 2010-04-01
CA2721241A1 (en) 2009-11-12
AR071633A1 (es) 2010-06-30
US20110064821A1 (en) 2011-03-17
KR20110010758A (ko) 2011-02-07
CL2009001076A1 (es) 2010-09-24
PE20091829A1 (es) 2009-12-12
UY31809A (es) 2009-12-14
EP2271323A2 (en) 2011-01-12
JP2011522792A (ja) 2011-08-04

Similar Documents

Publication Publication Date Title
PE20091882A1 (es) Encapsulacion de agentes biologicamente activos
PE20050926A1 (es) Composicion y forma de dosificacion que comprende una molecula anfifilica como un vehiculo de suspension
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
AR062059A1 (es) Espuma farmaceutica con acido graso
CL2013002550A1 (es) Una formulacion farmaceutica inyectable subcutanea liquida estable altamente concentrada de un anticuerpo anti-her2 farmaceuticamente activo que consiste esencialmente de trastuzumab; his/hci un agente estabilizador y un surfactante no ionico; kit y su uso para tratar enfermedades tales como cancer (divisional de solicitud n°0269-2012).
PE20121170A1 (es) Composicion de insulina de accion prolongada
AR095081A1 (es) Compuestos químicos
EA201391030A1 (ru) Композиции моноциклина для местного применения и способы их применения
CO6481009A2 (es) Preparación cosmética para el cabello y médtodo para la aplicación de la misma
MX2023007368A (es) Ligandos de integrina y usos de estos.
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
PE20110927A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisolpino y un antagonista de angiotensina ii
AR052545A1 (es) Suspension no acuosa inyectable
PE20161242A1 (es) Formulaciones de lipidos para la administracion de arn mensajero
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
BR112014013175A2 (pt) composições de liberação prolongada baseadas em lipídios anfipáticos
PE20110449A1 (es) Emulsiones modificadas de liberacion de medicina para aplicacion a la piel o la mucosa vaginal
AR076123A1 (es) Dispositivo de suministro de droga zootecnica. metodo.
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
GT200200065A (es) Composicion parenteral reconstituible
PE20210413A1 (es) Formulacion liquida estable que comprende etelcalcetida (amg416), un agente tamponante y agente de tonicidad
CR9468A (es) Oblea que contiene hormonas esteroides
BRPI0518869A2 (pt) agentes citotàxicos compreendendo taxanos
MX2007011039A (es) Sistema de solvente para aumentar la solubilidad de agentes farmaceuticos.
ES2625873T3 (es) Método de preparación de micropartículas biodegradables que contienen fármacos

Legal Events

Date Code Title Description
FC Refusal